Login
$ALLO
$0.81 +$0.00 (0.37%) After hours

Company Executives

Officer Age In this role Joined Source
Zachary Roberts Also a director
President and Chief Executive Officer
Title from the Form 8-K dated Jul 1, 2026
48 Not stated Not stated
David Chang, M.D., Ph.D. Also a director
President and CEO
Title from the Form 4 dated Mar 16, 2026
66 Not stated Not stated
Ben Beneski
Senior Vice President and Chief Technical Officer
49 Since 2025
1 year
2019
Earl Douglas
SVP, General Counsel
Title from the Form 4 dated Aug 21, 2026
63 Not stated Not stated

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 30, 2026 · updated by the 8-K of May 28, 2026

Directors
12
serving now
Independent
8 of 11
stated in the proxy; 1 not stated
Average tenure
7.3 years
from year joined
CEO also chairs the board
No
Arie Belldegrun, M.D.
Director Age On board Independent Committees Other public boards Pay Source
Arie Belldegrun, M.D.
76 2017
9 years
Not independent None stated None stated Not stated
David Chang, M.D., Ph.D.
66 2018
8 years
Not independent None stated None stated Paid as CEO
Franz Humer, Ph.D.
79 2018
8 years
Independent
Compensation Committee · Chair
None stated Not stated
Deborah Messemer
68 2018
8 years
Independent
Audit Committee · Chair
TPG Inc., PayPal Holdings, Inc. Not stated
Vicki Sato, Ph.D.
77 2021
5 years
Independent
Research and Development Committee
Vir Biotechnology, Inc. Not stated
Owen Witte, M.D.
76 2018
8 years
Independent
Nominating and Corporate Governance Committee · Chair
None stated Not stated
Elizabeth Barrett
63 2021
5 years
Independent
Audit Committee Compensation Committee
Sage Therapeutics, Inc. Not stated
John DeYoung
63 2018
8 years
Independent
Compensation Committee International and Business Development Oversight Committee
None stated Not stated
Joshua Kazam
49 2017
9 years
Not independent None stated None stated Not stated
Stephen Mayo, Ph.D.
64 2022
4 years
Independent
Audit Committee Research and Development Committee
Sarepta Therapeutics, Inc., Merck & Co., Inc. Not stated
Zachary Roberts Joined May 28, 2026
- - - - - -
Todd Sisitsky Leaving at the meeting
54 2018
8 years
Independent
Nominating and Corporate Governance
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

7 disclosed in the proxy filed Apr 30, 2026
Pfizer
Pfizer held 22,032,040 shares of our common stock based on the Schedule 13D/A filed on February 13, 2026 with the SEC
Amount not stated
April 2018

Asset Contribution Agreement under which we acquired assets and assumed liabilities from Pfizer, with Series A-1 Preferred Stock consideration, milestone payments and royalties

Bellco Capital Advisors Inc.
Our executive chair, Arie Belldegrun, M.D., is a trustee of the Belldegrun Family Trust, which controls Bellco Capital Advisors Inc.
$0.1 million
2022 and 2023

Sublease of office space in Los Angeles with rent payments made under the sublease

Bellco Capital Advisors Inc.
Our executive chair, Arie Belldegrun, M.D., is a trustee of the Belldegrun Family Trust, which controls Bellco Capital Advisors Inc.
$0.3 million
2024 and 2025

New sublease of 2,218 square feet of office space in Los Angeles, with base rent paid and tenant improvement contributions

Arie Belldegrun, M.D.
Member of the Company’s Board of Directors and a greater than 5% stockholder
Amount not stated

Purchased 344,828 shares of common stock in the 2024 registered offering under the Securities Purchase Agreement at $2.90 per share

David Chang, M.D., Ph.D.
The Company’s President and Chief Executive Officer, a member of the Company’s Board of Directors and a greater than 5% stockholder
Amount not stated

Purchased 344,828 shares of common stock in the 2024 registered offering under the Securities Purchase Agreement at $2.90 per share

Geoffrey Parker
The Company’s Chief Financial Officer
Amount not stated

Purchased 344,828 shares of common stock in the 2024 registered offering under the Securities Purchase Agreement at $2.90 per share

TPG Capital BD, LLC
Affiliate of TPG Inc., of which Todd Sisitsky, a member of our Board of Directors, has served as President and on the Board of Directors
$456,912
2026

Acted as co-manager in the 2026 public offering and purchased 3,807,600 shares at $1.88 per share, with an aggregate underwriting discount

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support